mRNA-Rv1387-Rv0287-Rv1788
Candidate Overview
The vaccine consists of three antigens delivered with the mRNA platform. Monovalent antigens were cloned into mRNA constructs containing a 5’ cap, 5’ untranslated region (UTR), 3’ UTR, and a polyadenylation signal, subjected to in vitro transcription using N1-methylpseudouridine, and encapsulated in lipid nanoparticles containing ALC-0315, 18:1 (Δ9-Cis) PE (DOPE), cholesterol, and 14:0 PEG2000 PE.
Sponsor / Lead Developer: Harvard Medical School
Primary Indication: Prevention of Mtb infection or sustained infection
Other Indication(s): Prevention of TB disease
Target Population(s): To be determined
Target Route of Administration: To be determined
Immune tissue localization: Lung and Lymph node
Immunological responses: B-cell/Antibody and T-cell
Preclinical Animal Models: Mouse and Nonhuman primate
Intended to elicit trained immunity: No
Additional Immunologic Response Information
HYPOTHESIZED | DEMONSTRATED |
|
| Immune Response | B-cell/Antibody T-cell |
|
| T-cell phenotype | CD4 CD8 |
|
| T-cell functional profile | IFN-γ TNF-α IL-17 |
|
| Characteristics of B-cell response | Serum IgG response to Rv1387 | |
| Preferential immune tissue localization | Lung Lymph node |
|
| Trained immunity | No | |